Navigation Links
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Date:9/18/2007

cure rate compared to a 79.8% cure rate seen with the combination of piperacillin/tazobactam. The study also highlighted that resistance to piperacillin/tazobactam in bacteria causing pneumonia was higher than doripenem, especially among strains of Pseudomonas aeruginosa and Klebsiella pneumoniae.

A second study demonstrated that 500 mg of doripenem administered intravenously every eight hours (500 mg IV q8h) was as clinically effective and well tolerated as standard therapy with imipenem given as 500 mg intravenously every six hours (500 mg IV q6h) or 1 g every eight hours (1 g IV q8h) in patients with ventilator-associated pneumonia, including in high-risk patients, such as the elderly. Overall clinical cure rates were 68.3% for doripenem and 64.8% for imipenem. For those patients with Pseudomonas aeruginosa infection, doripenem demonstrated a 65% clinical cure rate compared to a 36% clinical cure rate seen with imipenem.

"These studies demonstrate that doripenem may be effective against a major cause of nosocomial pneumonia, Pseudomonas aeruginosa, which is one of the most difficult bacteria to treat," said Michael Niederman, M.D., Professor of Medicine, State University of New York at Stony Brook and Chairman of the Department of Medicine at Winthrop University Hospital in Mineola, New York. "Additionally, these troubling bacteria demonstrated a low rate of resistance to doripenem, which is an important factor in determining which antibiotic may work most effectively against the infection."

The use of doripenem in the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is under standard regulatory review in the United States and Europe. These data, along with the regulatory submissions, demonstrate the ongoing commitment of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., to developing novel drugs for the anti-infective market.

Study Results

In a Phase III, open-label, randomized, multi-cent
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,
L.L.C.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 21, 2011 MicroAire Surgical Instruments ... for carpal tunnel syndrome.  MicroAire,s new device, called ... assembly that allows surgeons to treat carpal tunnel ... wrist – thereby avoiding full open-hand surgery through ...
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
Cached Medicine Technology:MicroAire Introduces New SlimLine™ ECTR Cannula 2
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... 22, 2014Hemoglobin A1c is the standard measurement for assessing ... levels of A1c are typically measured every few months ... data-based model that accurately estimates A1c using self-monitored blood ... & Therapeutics ( DTT ), a peer-reviewed journal ... available free on the DTT website at ...
(Date:4/22/2014)... April 2014. The latest scientific advances and emerging therapies ... 2014, the main annual meeting of the Heart Failure ... Journalists will also hear breaking news on acute heart ... Failure, which is part of the main congress. , ... Greece, at the Megaron Athens International Conference Centre (MAICC). ...
(Date:4/22/2014)... at the University of Utah (U of U) has ... separate cases, U of U researchers and their colleagues ... Journal of Human Genetics . The software, Phevor (Phenotype ... unknown gene mutations by analyzing the exomes, or areas ... made, in individual patients and small families. , ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated coverage of ... by researchers at the University of Michigan Health System. ... age of 18 at home, and adults with private ... adults to support universal coverage of birth control medications, ... Journal of the American Medical Association ( JAMA ...
Breaking Medicine News(10 mins):Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... BOULDER, Colo., Aug. 25 Bioelements has ... www.ro o m214.com ) to support research, ... and online initiatives. "Room 214 was chosen as our ... consumer behavior," said Callie Lushina, Vice President of Marketing for ...
... , , Says Damage ... , , WASHINGTON, Aug. 25 The ... ) board to remove CEO John Mackey as Chairman and to begin ... Foods, lead independent director, Dr. John Elstrott, yesterday afternoon. Citing the ...
... ... across the nation take a collective step to improve their health through exercise and increased ... that may unlock the secret to living longer and healthier lives. , ... Cambridge, MA (Vocus) August 25, 2009 -- This ...
... CINCINNATI, Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... financial results for the second quarter ended June 30, 2009. ... heavy growth in prescription sales and pharmacy transfers. Gross margins ... quarter was $396,271. , , "Consumers are ...
... , LOUISVILLE, Colo., Aug. 25 According ... Reconstructive Surgery Journal , the official journal of the American ... to be a safe and effective treatment option for fat ... Lipo to be an enhanced fat removal and transfer system ...
... in unpasteurised food has been detected in unusually high ... with the condition pre-eclampsia. These results are important ... indicator of pre-eclampsia and may help scientists to understand ... Scientists at the University of Leeds took blood ...
Cached Medicine News:Health News:Bioelements Selects Room 214 as Their Social Media and Online Marketing Agency 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 3Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 4Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 2Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 3Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 2Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 3Health News:New link between pre-eclampsia and diet 2
... time-consuming tasks and delivers consistently ... productivity and ensure testing accuracy ... offers automated reticulocyte counts and ... excellent sensitivity, specificity and efficiency ...
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... bi-polar CryoCor CryoBlator Series of Cryoablation Catheters ... catheter design with the two-stage cooling system ... maximize the delivery of cryoenergy to the ... work together to create the transmural lesions ...
... 5 software, the latest from Quality ... management application designed specifically for implementing ... system. The superior design, functionality, security, ... tool for managing a quality program., ...
Medicine Products: